ImmunityBio (NasdaqGS:IBRX) completed enrollment early in its pivotal Phase 2 bladder cancer trial for ANKTIVA. Interim analysis showed a statistically significant improvement in complete response ...

After partnering with Depend last year following his bladder cancer surgery, Colorado head coach Deion Sanders brought his story to life in his first commercial for the company.

Pfizer (NYSE:PFE) and Astellas Pharma reported positive pivotal Phase 3 results for PADCEV plus Keytruda in muscle invasive bladder cancer. The EV-304 (KEYNOTE-B15) trial showed a substantial ...

An aggressive bladder cancer diagnosis made 2025 one of the toughest years of Deion Sanders’ life. Coach Prime underwent a ...

Dr. Pooja Ghatalia presents findings from RETAIN-2, a single-arm phase 2 non-randomized trial evaluating a ...

A combination of Merck’s Keytruda and Pfizer’s Padcev could offer a chemotherapy-free treatment alternative for patients with ...

UroGen Pharma's ZUSDURI is positioned for accelerated adoption following a permanent J-Code in 2026. Read more on URGN stock and why it is a Buy.

Phase II study tested combination of sacituzumab govitecan plus pembrolizumab ...

To further complicate clinicians’ treatment decisions, Padcev-Keytruda has become the new standard of care in first-line metastatic bladder cancer, raising the possibility that some physicians might ...

USA: A recent systematic review and meta-analysis published in Diabetes Research and Clinical Practice has unveiled compelling evidence that type 1 diabetes may be a significant and ...

Protara Therapeutics has touted a 66% complete response (CR) rate for its cell therapy among certain bladder cancer patients ...

Colorado football coach Deion Sanders was diagnosed with an aggressive form of bladder cancer earlier this year, had surgery to remove the organ and is now considered cured by his doctors, the Pro ...